Traws Pharma, Inc. financial data

Symbol
TRAW on Nasdaq
Location
Newtown, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 185% % -0.16%
Return On Equity 415% %
Return On Assets -74% %
Operating Margin -698% % 99%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7,990,867 shares 164%
Common Stock, Shares, Outstanding 7,131,151 shares 136%
Entity Public Float $9,600,000 USD -61%
Common Stock, Value, Issued $71,000 USD 137%
Weighted Average Number of Shares Outstanding, Basic 8,818,859 shares 817%
Weighted Average Number of Shares Outstanding, Diluted 8,818,859 shares 817%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,903,000 USD 1185%
Revenue from Contract with Customer, Excluding Assessed Tax $57,000 USD 0%
Research and Development Expense $9,262,000 USD -31%
General and Administrative Expense $9,665,000 USD -11%
Operating Income (Loss) $15,785,000 USD 89%
Net Income (Loss) Attributable to Parent $13,309,000 USD 53%
Earnings Per Share, Basic -5 USD/shares 87%
Earnings Per Share, Diluted -5 USD/shares 87%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current $92,000 USD -73%
Assets, Current $9,625,000 USD 7.9%
Property, Plant and Equipment, Net $7,000 USD -42%
Other Assets, Noncurrent $240,000 USD 23900%
Assets $12,443,000 USD 39%
Accounts Payable, Current $5,105,000 USD -6.7%
Employee-related Liabilities, Current $774,000 USD 34%
Accrued Liabilities, Current $2,782,000 USD 5%
Contract with Customer, Liability, Current $226,000 USD 0%
Liabilities, Current $7,887,000 USD -5.5%
Contract with Customer, Liability, Noncurrent $2,508,000 USD -8.3%
Liabilities $7,898,000 USD -28%
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,000 USD
Retained Earnings (Accumulated Deficit) $632,541,000 USD -2.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4,545,000 USD
Liabilities and Equity $12,443,000 USD 39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,437,000 USD -23%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 7,131,151 shares 136%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,401,000 USD -22%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,420,000 USD 19%
Deferred Tax Assets, Valuation Allowance $36,840,000 USD -79%
Deferred Tax Assets, Gross $36,840,000 USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $13,270,000 USD 53%
Property, Plant and Equipment, Gross $84,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $28,324,000 USD -62%
Preferred Stock, Shares Issued 7,440 shares 0%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 6,737 shares -9.4%
Amortization of Intangible Assets $14,000 USD
Depreciation, Depletion and Amortization $1,000 USD -75%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $735,000 USD -47%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%